vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and TOOTSIE ROLL INDUSTRIES INC (TR). Click either name above to swap in a different company.
TOOTSIE ROLL INDUSTRIES INC is the larger business by last-quarter revenue ($196.3M vs $180.9M, roughly 1.1× AVANOS MEDICAL, INC.). TOOTSIE ROLL INDUSTRIES INC runs the higher net margin — 14.7% vs -0.7%, a 15.4% gap on every dollar of revenue. On growth, TOOTSIE ROLL INDUSTRIES INC posted the faster year-over-year revenue change (1.5% vs 0.7%). TOOTSIE ROLL INDUSTRIES INC produced more free cash flow last quarter ($61.0M vs $21.3M). Over the past eight quarters, TOOTSIE ROLL INDUSTRIES INC's revenue compounded faster (13.2% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Tootsie Roll Industries is an American manufacturer of confectionery based in Chicago, Illinois. Its best-known products include the namesake Tootsie Rolls and Tootsie Pops. Tootsie Roll Industries currently markets its brands internationally in Canada, Mexico, and over 75 other countries.
AVNS vs TR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $196.3M |
| Net Profit | $-1.3M | $28.8M |
| Gross Margin | 47.5% | 35.7% |
| Operating Margin | 1.4% | 17.0% |
| Net Margin | -0.7% | 14.7% |
| Revenue YoY | 0.7% | 1.5% |
| Net Profit YoY | 99.7% | 27.9% |
| EPS (diluted) | $-0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $196.3M | ||
| Q3 25 | $177.8M | $232.7M | ||
| Q2 25 | $175.0M | $155.1M | ||
| Q1 25 | $167.5M | $148.5M | ||
| Q4 24 | $179.6M | $193.4M | ||
| Q3 24 | $170.4M | $225.9M | ||
| Q2 24 | $171.7M | $150.7M | ||
| Q1 24 | $166.1M | $153.2M |
| Q4 25 | $-1.3M | $28.8M | ||
| Q3 25 | $-1.4M | $35.7M | ||
| Q2 25 | $-76.8M | $17.5M | ||
| Q1 25 | $6.6M | $18.1M | ||
| Q4 24 | $-397.3M | $22.5M | ||
| Q3 24 | $4.3M | $32.8M | ||
| Q2 24 | $1.8M | $15.6M | ||
| Q1 24 | $-900.0K | $15.8M |
| Q4 25 | 47.5% | 35.7% | ||
| Q3 25 | 48.4% | 34.1% | ||
| Q2 25 | 52.6% | 36.4% | ||
| Q1 25 | 53.6% | 35.3% | ||
| Q4 24 | 54.6% | 39.1% | ||
| Q3 24 | 54.5% | 34.1% | ||
| Q2 24 | 55.7% | 33.5% | ||
| Q1 24 | 57.1% | 32.7% |
| Q4 25 | 1.4% | 17.0% | ||
| Q3 25 | 0.1% | 13.9% | ||
| Q2 25 | -42.6% | 7.8% | ||
| Q1 25 | 6.1% | 15.5% | ||
| Q4 24 | -233.0% | 20.0% | ||
| Q3 24 | 7.0% | 15.6% | ||
| Q2 24 | 3.7% | 10.2% | ||
| Q1 24 | 2.4% | 7.3% |
| Q4 25 | -0.7% | 14.7% | ||
| Q3 25 | -0.8% | 15.3% | ||
| Q2 25 | -43.9% | 11.3% | ||
| Q1 25 | 3.9% | 12.2% | ||
| Q4 24 | -221.2% | 11.6% | ||
| Q3 24 | 2.5% | 14.5% | ||
| Q2 24 | 1.0% | 10.4% | ||
| Q1 24 | -0.5% | 10.3% |
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-1.66 | — | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $-8.64 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $0.04 | — | ||
| Q1 24 | $-0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $176.6M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $941.0M |
| Total Assets | $1.1B | $1.3B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $176.6M | ||
| Q3 25 | $70.5M | $119.8M | ||
| Q2 25 | $90.3M | $170.5M | ||
| Q1 25 | $97.0M | $176.6M | ||
| Q4 24 | $107.7M | $194.6M | ||
| Q3 24 | $89.0M | $163.2M | ||
| Q2 24 | $92.2M | $131.2M | ||
| Q1 24 | $75.8M | $159.4M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $941.0M | ||
| Q3 25 | $778.0M | $918.9M | ||
| Q2 25 | $776.3M | $893.1M | ||
| Q1 25 | $839.4M | $879.4M | ||
| Q4 24 | $828.5M | $870.7M | ||
| Q3 24 | $1.2B | $870.2M | ||
| Q2 24 | $1.2B | $841.4M | ||
| Q1 24 | $1.2B | $834.4M |
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $1.7B | $1.1B | ||
| Q2 24 | $1.7B | $1.1B | ||
| Q1 24 | $1.7B | $1.1B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $73.3M |
| Free Cash FlowOCF − Capex | $21.3M | $61.0M |
| FCF MarginFCF / Revenue | 11.8% | 31.1% |
| Capex IntensityCapex / Revenue | 3.8% | 6.3% |
| Cash ConversionOCF / Net Profit | — | 2.55× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $96.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $73.3M | ||
| Q3 25 | $14.0M | $62.2M | ||
| Q2 25 | $6.8M | $-8.5M | ||
| Q1 25 | $25.7M | $3.6M | ||
| Q4 24 | $57.9M | $68.8M | ||
| Q3 24 | $23.0M | $61.3M | ||
| Q2 24 | $27.8M | $-12.6M | ||
| Q1 24 | $-8.0M | $21.4M |
| Q4 25 | $21.3M | $61.0M | ||
| Q3 25 | $7.0M | $50.7M | ||
| Q2 25 | $-4.2M | $-16.0M | ||
| Q1 25 | $19.0M | $750.0K | ||
| Q4 24 | $53.1M | $64.7M | ||
| Q3 24 | $20.0M | $55.8M | ||
| Q2 24 | $21.9M | $-16.6M | ||
| Q1 24 | $-12.1M | $16.9M |
| Q4 25 | 11.8% | 31.1% | ||
| Q3 25 | 3.9% | 21.8% | ||
| Q2 25 | -2.4% | -10.3% | ||
| Q1 25 | 11.3% | 0.5% | ||
| Q4 24 | 29.6% | 33.5% | ||
| Q3 24 | 11.7% | 24.7% | ||
| Q2 24 | 12.8% | -11.0% | ||
| Q1 24 | -7.3% | 11.0% |
| Q4 25 | 3.8% | 6.3% | ||
| Q3 25 | 3.9% | 5.0% | ||
| Q2 25 | 6.3% | 4.8% | ||
| Q1 25 | 4.0% | 1.9% | ||
| Q4 24 | 2.7% | 2.1% | ||
| Q3 24 | 1.8% | 2.4% | ||
| Q2 24 | 3.4% | 2.6% | ||
| Q1 24 | 2.5% | 2.9% |
| Q4 25 | — | 2.55× | ||
| Q3 25 | — | 1.74× | ||
| Q2 25 | — | -0.49× | ||
| Q1 25 | 3.89× | 0.20× | ||
| Q4 24 | — | 3.06× | ||
| Q3 24 | 5.35× | 1.87× | ||
| Q2 24 | 15.44× | -0.81× | ||
| Q1 24 | — | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
TR
| Products | $194.3M | 99% |
| Rental And Royalty | $1.9M | 1% |
